Zura Bio: Holder reports 4.44% stake

Zura Bio Limited reports a joint Schedule 13G/A filing disclosing beneficial ownership of 4,215,930 Class A Ordinary Shares, equal to 4.44% of the class.

Rhea-AI Filing Summary

Zura Bio Limited reports a joint Schedule 13G/A filing disclosing beneficial ownership of 4,215,930 Class A Ordinary Shares, equal to 4.44% of the class. The percentage is calculated using 94,880,710 shares outstanding as of March 19, 2026 as reported in the issuer's Form 10-K.

The filing is made jointly by Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl under a Joint Filing Agreement dated May 15, 2026, and shows shared voting and dispositive power over the reported shares.

Insights

Corporate Governance Expert

Joint Schedule 13G/A shows a passive, disclosed >5% influence vector with shared control.

The filing lists 4,215,930 shares or 4.44% of Class A Ordinary Shares, with shared voting and dispositive power reported. The percentage is tied to March 19, 2026 outstanding shares in the issuer's Form 10-K.

Because the filing is a Schedule 13G/A and executed jointly, it signals coordinated reporting rather than an active change in control; subsequent amendments would reveal any shift in intent or additional accumulation.

Investor Relations Analyst

Disclosure clarifies ownership scale and reporting structure for investor records.

The joint filing identifies the reporting persons and their shared authority: shared voting and dispositive power over 4,215,930 shares. The joint filing agreement dated May 15, 2026 is attached as an exhibit.

For shareholders, this provides a clear public record of beneficial ownership; any material change would appear in future amendments or alternate Schedule types.

Key Figures

Beneficial ownership: 4,215,930 shares Percent of class: 4.44% Shares outstanding: 94,880,710 shares

3 metrics

Beneficial ownership 4,215,930 shares Amount beneficially owned by the reporting persons

Percent of class 4.44% Percent of Class A Ordinary Shares based on Form 10-K outstanding count

Shares outstanding 94,880,710 shares Shares outstanding reported in issuer's Form 10-K as of March 19, 2026

Key Terms

Schedule 13G/A, Beneficially owned, Joint Filing Agreement

3 terms

Schedule 13G/A regulatory

"joint Schedule 13G/A filing disclosing beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Amount beneficially owned: 4,215,930"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Joint Filing Agreement regulatory

"Joint Filing Agreement, dated May 15, 2026, is filed as Exhibit A"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake did Great Point Partners report in ZURA?

Great Point Partners, together with co‑filers, reported beneficial ownership of 4,215,930 shares, representing 4.44% of Class A Ordinary Shares. This percentage uses the issuer's disclosed 94,880,710 shares outstanding as of March 19, 2026 from its Form 10-K.

Who are the reporting persons on the Schedule 13G/A for ZURA?

The joint filing is made by Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl. They executed a Joint Filing Agreement dated May 15, 2026 to file this Schedule 13G/A jointly and share responsibility for the filing.

What voting and dispositive powers are reported in the filing?

The filing reports 0 sole voting and 0 sole dispositive power, and 4,215,930 shares of shared voting and shared dispositive power. The reporting persons thus indicate shared control over the reported shares rather than sole authority.

What source did the filing use to calculate the 4.44% figure?

The percentage is based on 94,880,710 shares outstanding, as reported by Zura Bio in its Form 10-K filed with the SEC on March 19, 2026. That outstanding share count was used to compute the 4.44% ownership percentage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 08:54 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Zura Bio Limited

(Name of Issuer)

Class A Ordinary Shares

(Title of Class of Securities)

G9TY5A101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G9TY5A101

1

Names of Reporting Persons

Great Point Partners, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,215,930.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,215,930.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,215,930.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.44 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): G9TY5A101

1

Names of Reporting Persons

Dr. Jeffrey R. Jay, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,215,930.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,215,930.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,215,930.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.44 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): G9TY5A101

1

Names of Reporting Persons

Ms. Lillian Nordahl

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,215,930.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,215,930.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,215,930.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.44 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Zura Bio Limited
(b)	Address of issuer's principal executive offices: 1489 W. Warm Springs Rd. #110, Henderson, NV 89014
Item 2.
(a)	Name of person filing: Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated May 15, 2026, a copy of which is filed with this SCHEDULE 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830
(c)	Citizenship: Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States.
(d)	Title of class of securities: Class A Ordinary Shares
(e)	CUSIP No.: G9TY5A101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,215,930
(b)	Percent of class: 4.44%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 4,215,930
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 4,215,930 Item 4 The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 94,880,710 shares outstanding as reported by the Issuer in its Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 19, 2026.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 4.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Great Point Partners, LLC

Signature:	/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:	Dr. Jeffrey R. Jay, M.D - Senior Managing Member
Date:	05/15/2026

Dr. Jeffrey R. Jay, M.D.

Signature:	/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:	Dr. Jeffrey R. Jay, M.D
Date:	05/15/2026

Ms. Lillian Nordahl

Signature:	/s/ Ms. Lillian Nordahl
Name/Title:	Ms. Lillian Nordahl
Date:	05/15/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G/A to which this Exhibit is attached, and such SCHEDULE 13G/A is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl